RNS Number : 9824T
Creo Medical Group PLC
26 June 2024
 




Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Result of AGM

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that all resolutions put to shareholders at the Company's Annual General Meeting held earlier today were duly passed.

 

The voting results will be made available on the Investor Relations section of the Company's website shortly: https://www.creomedical.com/en/investors/reports-and-presentations

 

Enquiries:

Creo Medical Group plc

www.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005



Cavendish Capital Markets Limited

+44 (0)20 7397 8900

Stephen Keys / Camilla Hume (NOMAD)


Michael Johnson (Sales)




Deutsche Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Euan Brown

+44 (0)20 7260 1000



Walbrook PR

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus / Sam Allen

Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

+44 (0)7867 984 082 

 

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com

 

A close-up of a device Description automatically generated

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGUNVKRSRUNURR
Grafico Azioni Creo Medical (LSE:CREO)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di Creo Medical
Grafico Azioni Creo Medical (LSE:CREO)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di Creo Medical